Last reviewed · How we verify
Macugen (EYE001)
Macugen (EYE001) is a small molecule drug developed by VALEANT PHARMS LLC, targeting vascular endothelial growth factor A (VEGF-A). It was approved by the FDA in 2004 for the treatment of exudative age-related macular degeneration. Macugen works by inhibiting the action of VEGF-A, a protein that promotes the growth of new blood vessels in the eye, which can lead to vision loss. The commercial status of Macugen is patented, and it is currently owned by VALEANT PHARMS LLC. Key safety considerations include potential eye inflammation and increased risk of endophthalmitis.
At a glance
| Generic name | EYE001 |
|---|---|
| Sponsor | Valeant Pharms Llc |
| Target | Vascular endothelial growth factor A |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
| First approval | 2004 |
Approved indications
- Exudative age-related macular degeneration
Common side effects
Key clinical trials
- Evaluation of Performance of MiYOSMART Photochromic and Clear Spectacle Lenses in Myopic Children (NA)
- Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration (PHASE2)
- EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome (PHASE1)
- Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration) (PHASE3)
- A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD. (PHASE2,PHASE3)
- Pegaptanib Sodium Compared to Sham Injection in Patients With DME Involving the Center of the Macula (PHASE2)
- Phase II/III Study of Anti-VEGF in Neovascular AMD (PHASE2,PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Macugen CI brief — competitive landscape report
- Macugen updates RSS · CI watch RSS
- Valeant Pharms Llc portfolio CI